Previous Next

ARCHIVE

№4' 2015

ONCOLOGY

International Medical Journal, Vol. 21., Iss. 4, 2015, P. 65−68.


THE EFFECTIVENESS OF ADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER


Basylaishvili S. Yu.

Kharkiv National Medical University, Ukraine

The purpose of the work was to study the effectiveness of various treatment options for stage 3A NSCLC using neoadjuvant and adjuvant chemotherapy and adjuvant radiotherapy. The study involved 89 stage 3A NSCLC patients treated at the thoracic department of Kharkov Regional Clinical Cancer Center from 2010 to 2014. The surveyed patients were divided into three groups. The first group (comparison) included 38 patients who received the following treatment: radical surgery followed by 4 cycles of adjuvant chemotherapy according to standard regimens. Patients of the second group (27 patients) received 2 cycles of preoperative chemotherapy before surgery and 3−4 weeks after the surgery they were conducted 4 courses of adjuvant chemotherapy. The third group consisted of 24 patients who underwent radical surgery followed by 2 cycles of chemotherapy and irradiation of the mediastinum on the linear accelerator VARIAN. One−year survival rate in group 1 was 57.2 %, in group 2 −− 75.3 %, in group 3 −− 81.2 %. Local recurrences in group 1 after one year of observation were found in 5 patients, in group 2 −− 2 patients, and in group 3 were not revealed. The two−year survival rate in group 1 was 47 %, in group 2 −− 66.1 %, in group 3 −− 73.8 %. Preoperative neoadjuvant chemotherapy gives partial effect less than in half of patients with NSCLC, thus its use is not always appropriate. Maximum 2−year survival of patients is observed after two cycles of chemotherapy after surgery and then radiotherapy. Radiotherapy allows reduction in the number of local recurrences.

Key words: stage 3A non−small cell lung cancer, polychemotherapy, surgery, radiotherapy, pathomorphism, complications, survival.


Go on Top